NTLA-2001
Intellia Therapeutics
['cardio', 'cardiomyopathy', 'crispr']
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022 
Pharmaceutical News - Direct Information